These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39092465)

  • 1. Disparity in Guideline-Based Antidiabetic Drugs Prescribing for Type 2 Diabetes Patients in Primary Healthcare Facilities Across China, 2017-2019.
    Fu M; Gong Z; Zhu Y; Li C; Li H; Shi L; Guan X
    Pharmacoepidemiol Drug Saf; 2024 Aug; 33(8):e5882. PubMed ID: 39092465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
    Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
    Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management and treatment goals in Polish patients with type 2 diabetes of short duration: results of the ARETAEUS2-Grupa study.
    Bała MM; Płaczkiewicz-Jankowska E; Leśniak W; Topór-Mądry R; Michałejko M; Jankowski M; Strzeszyński L; Sieradzki J; Czupryniak L;
    Pol Arch Med Wewn; 2013; 123(11):573-81. PubMed ID: 24241157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study.
    Ko SH; Kim DJ; Park JH; Park CY; Jung CH; Kwon HS; Park JY; Song KH; Han K; Lee KU; Ko KS;
    Medicine (Baltimore); 2016 Jul; 95(27):e4018. PubMed ID: 27399082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study.
    van Dalem J; Brouwers MCGJ; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Driessen JHM
    Diabetes Res Clin Pract; 2021 Jun; 176():108828. PubMed ID: 33894280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
    Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
    BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Yurgin N; Secnik K; Lage MJ
    Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study.
    Mahmoud F; Mueller T; Mullen A; Sainsbury C; Rushworth GF; Kurdi A
    Diabetes Obes Metab; 2024 Jul; 26(7):2684-2694. PubMed ID: 38558305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians.
    Boyc KS; Yurgin N; Lage MJ
    Adv Ther; 2007; 24(4):803-13. PubMed ID: 17901029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study.
    Liu CH; Chen ST; Chang CH; Chuang LM; Lai MS
    Public Health; 2017 Nov; 152():20-27. PubMed ID: 28719837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing for people with type 2 diabetes and renal impairment in Australian general practice: A national cross sectional study.
    Manski-Nankervis JE; Thuraisingam S; Sluggett JK; Lau P; Blackberry I; Ilomaki J; Furler J; Bell JS
    Prim Care Diabetes; 2019 Apr; 13(2):113-121. PubMed ID: 30262176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus.
    Lub R; Denig P; van den Berg PB; Hoogenberg K; de Jong-van den Berg LT
    Br J Clin Pharmacol; 2006 Dec; 62(6):660-5. PubMed ID: 16796700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns.
    Secrest MH; Azoulay L; Dahl M; Clemens KK; Durand M; Hu N; Targownik L; Turin TC; Dormuth CR; Filion KB
    Pharmacoepidemiol Drug Saf; 2020 Jan; 29 Suppl 1():86-92. PubMed ID: 31464069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.
    Datta-Nemdharry P; Thomson A; Beynon J; Donegan K
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):127-135. PubMed ID: 27642000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines.
    Wang TY; Eguale T; Tamblyn R
    BMC Health Serv Res; 2013 Oct; 13():442. PubMed ID: 24160916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network.
    Pinto D; Rodrigues AP; Nunes B
    Acta Med Port; 2019 May; 32(5):375-380. PubMed ID: 31166898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
    Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
    BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.
    Lamine F; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2016; 146():w14282. PubMed ID: 26922155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.